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A bs tr ac t
Background
There is no established standard chemotherapy for patients with locally advanced or 
metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study 
involving 86 patients to compare cisplatin plus gemcitabine with gemcitabine alone. 
After we found an improvement in progression-free survival, the trial was extended 
to the phase 3 trial reported here.
Methods
We randomly assigned 410 patients with locally advanced or metastatic cholangio-
carcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg 
per square meter of body-surface area) followed by gemcitabine (1000 mg per square 
meter), each administered on days 1 and 8, every 3 weeks for eight cycles, or gemcit-
abine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six 
cycles) for up to 24 weeks. The primary end point was overall survival.
Results
After a median follow-up of 8.2 months and 327 deaths, the median overall survival 
was 11.7 months among the 204 patients in the cisplatin–gemcitabine group and 
8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; 
95% confidence interval, 0.52 to 0.80; P<0.001). The median progression-free sur-
vival was 8.0 months in the cisplatin–gemcitabine group and 5.0 months in the 
gemcitabine-only group (P<0.001). In addition, the rate of tumor control among pa-
tients in the cisplatin–gemcitabine group was significantly increased (81.4% vs. 
71.8%, P = 0.049). Adverse events were similar in the two groups, with the exception 
of more neutropenia in the cisplatin–gemcitabine group; the number of neutrope-
nia-associated infections was similar in the two groups.
Conclusions
As compared with gemcitabine alone, cisplatin plus gemcitabine was associated 
with a significant survival advantage without the addition of substantial toxicity. 
Cisplatin plus gemcitabine is an appropriate option for the treatment of patients 
with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769.)
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Biliary tract cancer is an uncom-mon cancer in developed countries. There are approximately 1200 new cases in the 
United Kingdom1 and 9000 new cases in the Unit-
ed States per year, although the incidence is in-
creasing, perhaps related to gallstone disease.2 
Most patients have advanced disease at presenta-
tion and relapse despite surgery.3 Although ad-
vanced biliary tract cancer can have a response to 
chemotherapy, there is no recognized standard 
palliative regimen because no single randomized 
study has ever been sufficiently robust to define 
a schedule; fluoropyrimidines,4,5 cisplatin,6 and 
gemcitabine7,8 have shown activity.
Gemcitabine (Gemzar, Eli Lilly) treatment for 
biliary tract cancer has been increasingly pre-
scribed by oncologists who specialize in hepato-
biliary disease because of its use in pancreatic 
cancer. Cisplatin is known to have an additive or 
synergistic effect in combination with gemcitabine 
in a number of different tumor types (e.g., lung,9 
bladder,10 and head and neck11 cancers). We pre-
viously found an improvement in 6-month pro-
gression-free survival from 47.7% to 57.1% in a 
randomized, phase 2 trial (the Advanced Biliary 
Cancer [ABC]-01 trial) comparing cisplatin plus 
gemcitabine with gemcitabine alone; that trial in-
volved 86 patients.12 That study was extended to 
become a phase 3 trial (the ABC-02 trial) with a 
planned recruitment total of 400 patients and a 
primary end point of overall survival.
Me thods
study Design
This randomized, controlled, phase 3 trial was de-
signed and developed by the ABC-02 Trial Man-
agement Group under the auspices of the Upper 
Gastrointestinal Cancer Clinical Studies Group of 
the United Kingdom National Cancer Research 
Institute. The study was conducted by investiga-
tors at 37 centers in the United Kingdom, and 
data were collected and analyzed at the Cancer 
Research United Kingdom and University College 
London Cancer Trials Centre, London. The trial 
was initially designed as a randomized, phase 2 
study involving 86 patients (the ABC-01 trial), 
conducted between February 2002 and June 2004. 
The trial was extended into a phase 3 trial (the 
ABC-02 trial) because of an apparent benefit in 
progression-free survival; this extension used a 
similar approach to that described previously.13 
The same treatment regimens and eligibility cri-
teria were used in both phases. Investigators were 
unaware of the overall survival analysis in the 
ABC-01 trial, as mandated by the independent 
data and safety monitoring committee.
This trial was approved by a research ethics 
committee, and all necessary regulatory approv-
als were obtained. All patients were required to 
give written informed consent before random 
assignment, and the trial was conducted in ac-
cordance with the Declaration of Helsinki. An 
independent data and safety monitoring board 
regularly reviewed the data on safety.
Lilly Oncology provided the investigators with 
gemcitabine at no cost but was not involved in 
the accrual or analysis of the data, the interpre-
tation of the results, or the preparation of the 
manuscript.
Patients
Patients were eligible for the study if they were 18 
years of age or older and had received a histopatho-
logical or cytologic diagnosis of nonresectable, 
recurrent, or metastatic biliary tract carcinoma 
(intrahepatic or extrahepatic cholangiocarcinoma, 
gallbladder cancer, or ampullary carcinoma); an 
Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0, 1, or 2 (on a scale ranging 
from 0 to 5, with lower scores indicating a high-
er level of functioning); and an estimated life ex-
pectancy of more than 3 months. Other eligibility 
criteria were adequate hematologic and biochem-
ical function, in particular a total bilirubin level of 
1.5 times the upper limit of the normal range or 
less, liver-enzyme levels that were five times the 
upper limit of the normal range or less, renal func-
tion with levels of serum urea and serum creati-
nine that were less than 1.5 times the upper limit 
of the normal range, and a calculated glomerular 
filtration rate of 45 ml per minute or higher.
Treatment
Patients were randomly assigned to receive cis-
platin plus gemcitabine or gemcitabine alone for 
up to 24 weeks. In the cisplatin–gemcitabine group, 
each cycle comprised cisplatin (25 mg per square 
meter of body-surface area) followed by gemcit-
abine (1000 mg per square meter), each adminis-
tered on days 1 and 8 every 3 weeks, initially for 
four cycles. In the gemcitabine-only group, gem-
citabine was administered at a dose of 1000 mg 
per square meter on days 1, 8, and 15 every 4 weeks, 
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initially for three cycles. Cisplatin plus gemcita-
bine was administered on an outpatient basis as a 
2-hour infusion (1 liter of 0.9% saline including 
cisplatin, 20 mmol of potassium chloride, and 
8 mmol of magnesium sulfate over 1 hour followed 
by 500 ml of 0.9% saline over 30 minutes before 
the administration of gemcitabine). All patients 
received gemcitabine as a 30-minute infusion.
If patients did not have disease progression at 
12 weeks, they could continue with another 12 
weeks of the same regimen. Dose modifications 
were defined per protocol, and modifications and 
delays were allowed for hematologic toxicity, ab-
normal renal function, nausea, vomiting, periph-
eral neuropathy, edema, or tinnitus. Treatment was 
discontinued at 24 weeks or because of disease 
progression, patient or clinician choice, or unac-
ceptable toxic effects. Biliary obstruction per se 
was not considered to be disease progression in 
the absence of radiologically confirmed disease 
progression, and treatment could be recommenced 
after further biliary stenting and normalization 
of liver function.
Assessments
Patients were seen at the start of every cycle for a 
physical examination, monitoring of symptoms 
and toxic effects, assessment of renal function, 
and a complete blood count. Tumor response, mea-
sured according to the Response Evaluation Cri-
teria in Solid Tumors (RECIST) 1.0 criteria,14 was 
assessed by means of computed tomography (CT) 
or magnetic resonance imaging (MRI) at week 12 
and again at week 24 in patients who completed 
treatment (confirmatory scans were not required). 
Tumor control was defined as a complete response, 
a partial response, or stable disease. For the end 
point of progression-free survival, progressive dis-
ease was defined as either objective tumor pro-
gression based on RECIST 1.0 criteria or the 
confirmed emergence of local nonprimary, met-
astatic, or nodal disease. After the end of the 
study treatment, patients were seen in the clinic 
every 3 months. Follow-up visits consisted of clin-
ical assessment and either CT or MRI to assess 
tumor progression. Once progressive disease was 
documented, patients underwent follow-up for sur-
vival only.
Statistical Analysis
The primary outcome was overall survival, and 
the secondary outcomes were progression-free sur-
vival, tumor response, and adverse events. The trial 
was designed to have 80% power to detect an 
increase in median survival from 8 months in pa-
tients receiving gemcitabine alone to 11 months 
in patients receiving cisplatin plus gemcitabine. 
A total of 354 patients would be required to reach 
315 events, based on the use of the log-rank test 
with a two-sided significance level of 5% and as-
suming that the trial would recruit for 3 years 
with at least 6 months of follow-up for each pa-
tient. To allow for dropouts and to ensure that we 
had sufficient evidence to meet the trial objec-
tives, we aimed to recruit 400 patients. Patients 
were randomly assigned by telephone by the Can-
cer Research United Kingdom and University Col-
lege London Cancer Trials Centre, which coordi-
nated the trial. Randomization was conducted 
with the use of a minimization algorithm strati-
fied according to the primary tumor site, extent 
of disease (locally advanced vs. metastatic), per-
formance status, previous therapy, and recruiting 
center.
All analyses were performed on an intention-
to-treat basis. Overall survival was calculated from 
the date of randomization until the date of death. 
Progression-free survival was measured from ran-
domization until the date of disease progression 
or death. Patients who did not have disease pro-
gression and patients who died were excluded at 
the date of their last follow-up. Overall survival 
and progression-free survival were analyzed with 
the use of Kaplan–Meier curves and the log-rank 
test. A Cox proportional-hazards model was used 
to estimate the hazard ratios. Toxic effects were 
categorized according to the National Cancer In-
stitute’s Common Toxicity Criteria for Adverse 
Events, version 3. All analyses were performed 
with the use of Stata 10.1 software (Stata). The 
database was closed for analysis in June 2009.
R esult s
We recruited 410 patients from 37 centers in the 
United Kingdom across the National Cancer Re-
search Network between February 2002 and Octo-
ber 2008. A total of 204 patients received cisplatin 
plus gemcitabine, and 206 received gemcitabine 
alone (Fig. 1). The median follow-up time was 8.2 
months. At the time of the final analysis, 327 
deaths had occurred, and 362 patients (88.3%) had 
tumor progression. Baseline characteristics were 
well balanced between the two groups (Table 1). 
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There was an insignificant difference between the 
numbers of patients with locally advanced disease 
in the two groups (27.0% in the cisplatin–gem-
citabine group vs. 23.8% in the gemcitabine-only 
group, P = 0.46). The majority of patients had ei-
ther a histologic or a cytologic diagnosis of an 
adenocarcinoma or a carcinoma (99.0%). Two pa-
tients had an adenosquamous tumor; one was a 
squamous-cell carcinoma and one was a carcino-
sarcoma.
Treatment Compliance
At the end of the first 12 weeks, treatment com-
pliance was similar in the two groups, with 66.5% 
receiving three cycles of gemcitabine alone and 
73.5% receiving four cycles of cisplatin plus gem-
citabine; however, in the treatment period over-
all, more patients in the gemcitabine-only group 
discontinued planned treatment prematurely, pri-
marily because of disease progression (49 patients 
in the gemcitabine-only group vs. 26 patients in 
the cisplatin–gemcitabine group, P = 0.004). This 
discontinuation is reflected in the median dura-
tion of treatment (14 weeks in the gemcitabine-
only group vs. 21 weeks in the cisplatin–gemcit-
abine group, P = 0.003). Significantly more patients 
in the cisplatin–gemcitabine group than patients 
in the gemcitabine-only group went on to start 
the second 12 weeks of treatment (63% vs. 52%, 
P = 0.02). In the first 12 weeks of treatment, an 
average of 92% of the planned dose was delivered 
to patients in the gemcitabine-only group, as com-
pared with 95% in the cisplatin–gemcitabine group 
(P = 0.95); however, in the second 12 weeks, the 
average was 69% in the gemcitabine-only group as 
compared with 88% in the cisplatin–gemcitabine 
group (P = 0.046). Among the 72 patients who 
went on to receive second-line therapy, 13 of 36 
patients in the gemcitabine-only group (36%) re-
ceived a platinum-based agent as compared with 
10 of 36 patients in the cisplatin–gemcitabine group 
(28%) (P = 0.45). Four patients from each group 
received no treatment during the trial (Fig. 1). 
Tables 1 through 3 in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org, provide details of noncompliance and 
dose modifications.
Tumor Response
Objective tumor response was measurable in 303 
patients (patients were not required to have mea-
surable disease at study entry). Tumor control (com-
plete or partial response or stable disease) was 
achieved in 131 of 161 patients who received cis-
platin plus gemcitabine (81.4%), as compared with 
102 of 142 patients who received gemcitabine alone 
(71.8%) (P = 0.049). One patient from each group 
achieved a complete response. There were no dif-
ferences in the rate of response between the gall-
bladder and cholangiocarcinoma subgroups (Ta-
ble 4 in the Supplementary Appendix).
Survival and Disease Progression
The final analysis was event-driven and performed 
8 months after the last patient was enrolled in 
the trial, at which point 327 deaths had occurred 
(79.8%), including 10 noncancer deaths and 37 
deaths for which the cause was unknown. A total 
of 362 patients had tumor progression (88.3%), 
of whom 278 died. There was one death from 
renal failure in the cisplatin–gemcitabine group; 
this death may have been related to cisplatin.
Figure 2A shows the Kaplan–Meier curves for 
overall survival. The median survival in the cis-
platin–gemcitabine group was 11.7 months (95% 
confidence interval [CI], 9.5 to 14.3), as compared 
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Figure 1. Patient Enrollment, Randomization, and Treatment.
Measurable disease was not a study-entry criterion; therefore, not all pa-
tients were assessed for an objective tumor response.
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with 8.1 months (95% CI, 7.1 to 8.7) for the gem-
citabine-only group (P<0.001). Patients who re-
ceived cisplatin plus gemcitabine were 36% less 
likely to die at any time than those who received 
gemcitabine alone (hazard ratio, 0.64; 95% CI, 
0.52 to 0.80). Adjustment for the randomization 
Table 1. Baseline Characteristics of the Study Participants, According to Treatment Group.*
Variable
Gemcitabine 
(N = 206)
Cisplatin plus Gemcitabine 
(N = 204) P Value
Age — yr
Median 63.2 63.9 0.88
Range 23.4–84.8 32.8–81.9
Sex — no. (%)
Female 108 (52.4) 108 (52.9) 0.92
Male 98 (47.6) 96 (47.1)
Extent of disease — no. (%)
Locally advanced 49 (23.8) 55 (27.0) 0.46
Metastatic 157 (76.2) 149 (73.0)
Primary tumor site — no. (%)
Gallbladder 76 (36.9) 73 (35.8) 0.87
Bile duct 119 (57.8) 122 (59.8)
Ampulla 11 (5.3) 9 (4.4)
Type of tumor — no. (%)
Adenocarcinoma 191 (92.7) 186 (91.2) 0.27
Carcinoma, type not specified 12 (5.8) 17 (8.3)
Adenosquamous carcinoma 2 (1.0) 0
Squamous-cell carcinoma 1 (0.5) 0
Carcinosarcoma 0 1 (0.5)
ECOG performance-status score — no. (%)
0 64 (31.1) 66 (32.4) 0.72
1 117 (56.8) 111 (54.4)
2 24 (11.7) 27 (13.2)
Unknown 1 (0.5) 0
Previous therapy — no. (%)
No 50 (24.3) 50 (24.5) 0.96
Yes 156 (75.7) 154 (75.5)
Type of previous therapy — no. (%)
Curative surgery 48 (23.3) 37 (18.1) 0.20
Palliative surgery 40 (19.4) 37 (18.1) 0.74
Laparotomy 49 (23.8) 48 (23.5) 0.95
Biliary stenting 92 (44.7) 93 (45.6) 0.85
Radiotherapy 5 (2.4) 3 (1.5) 0.48
Adjuvant chemotherapy 5 (2.4) 3 (1.5) 0.74
Photodynamic therapy 1 (0.5) 1 (0.5) 1.00
Other therapy 81 (39.3) 76 (37.3) 0.14
* ECOG denotes Eastern Cooperative Oncology Group. ECOG scores range from 0 to 5, with lower scores indicating a 
higher level of functioning.
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stratification factors did not significantly alter 
this outcome (hazard ratio, 0.67; 95% CI, 0.54 to 
0.84). Figure 2B shows the Kaplan–Meier curves 
for progression-free survival. Cisplatin plus gem-
citabine significantly improved progression-free 
survival, with a median of 8.0 months (95% CI, 
6.6 to 8.6) in the cisplatin–gemcitabine group as 
compared with 5.0 months (95% CI, 4.0 to 5.9) in 
the gemcitabine-only group (P<0.001). The haz-
ard ratio for disease progression was 0.63 (95% 
CI, 0.51 to 0.77). The 6-month progression-free 
survival rate was 59.3% in the cisplatin–gemcit-
abine group and 42.5% in the gemcitabine-only 
group.
Figure 3 shows the hazard ratios for death ac-
cording to prespecified baseline factors. There was 
no evidence of a difference in treatment effect 
between the subgroups.
Adverse Events
Table 2 summarizes the grades 3 and 4 adverse 
events reported during the trial. There was a non-
significant excess of neutropenia in the cisplatin–
gemcitabine group; infections were similar in the 
two groups. Liver function was significantly worse 
in the gemcitabine-only group (27.1%) than in the 
cisplatin–gemcitabine group (16.7%). We think this 
difference probably reflects better control of dis-
ease in the cisplatin–gemcitabine group. Other-
wise, adverse events were similar between the two 
groups. Seven suspected, unexpected serious ad-
verse reactions were reported during the trial, oc-
curring in seven patients, all of whom were in the 
gemcitabine-only group.
Discussion
These data provide evidence that cisplatin plus 
gemcitabine is an effective treatment option for 
locally advanced or metastatic biliary tract cancer. 
Patients treated with cisplatin plus gemcitabine 
lived an average of 3.6 months longer than those 
treated with gemcitabine alone. This benefit was 
achieved with the use of an outpatient schedule, 
and adverse events were similar between the two 
treatment regimens. These data are consistent with 
the known preclinical15 and clinical9-11 synergies 
of cisplatin and gemcitabine.
In the ABC-01 trial, there was an increase in 
grade 3 or 4 fatigue in patients who received cis-
platin plus gemcitabine (28.6%, vs. 9.1% in the 
gemcitabine-only group12). However, this increase 
was not observed in the ABC-02 trial (18.7% vs. 
16.6%). Patients who received gemcitabine had a 
significantly increased incidence of grade 3 or 4 
abnormal liver-function tests (27.1%, vs. 16.7% for 
cisplatin–gemcitabine; P = 0.01), possibly as a result 
of inferior disease control and biliary drainage.
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Figure 2. Outcomes in Patients with Biliary Tract Cancer Who Received 
Gemcitabine Alone versus Cisplatin plus Gemcitabine.
Panel A shows Kaplan–Meier estimates of overall survival, and Panel B 
shows Kaplan–Meier estimates of progression-free survival. CI denotes 
confidence interval.
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Until the results of the ABC-01 study12 and 
now these data were reported, nonrandomized, 
phase 2 studies provided the best evidence base 
for the treatment of biliary tract cancer. A system-
atic review in 2005 identified 13 studies of the 
use of gemcitabine alone or in combination with 
other agents.16 Three of these studies involved the 
use of a cisplatin–gemcitabine regimen and showed 
median survivals of 4.6, 6.5, and 10.4 months. 
A Japanese trial involving 83 patients conducted 
with the use of the same treatment regimens as 
those used in the ABC-02 trial17 showed a median 
overall survival of 11.2 months in the cisplatin–
gemcitabine group and 7.7 months in the gemcit-
abine-only group, consistent with our data. The 
French Biliary Cancers: EGFR Inhibitor, Gemcit-
abine and Oxaliplatin (BINGO) trial (ClinicalTrials 
.gov number, NCT00552149) randomly assigned 
101 patients to receive gemcitabine plus oxaliplatin 
with or without cetuximab.18 In the BINGO trial, 
investigators reported 4-month progression-free 
survival rates of 50% in the gemcitabine–oxalipla-
tin group and 61% in the gemcitabine–oxaliplatin 
plus cetuximab group. These findings compare 
with a 4-month progression-free survival rate of 
approximately 70% in the cisplatin–gemcitabine 
group in the ABC-02 trial.
The management of biliary tract cancer has 
become multidisciplinary, with improvements in 
stenting, systemic chemotherapy,12 and new meth-
ods such as photodynamic therapy.19 Central to the 
case for active management is the possibility that 
small improvements in bile-duct lumen size will 
have a significant effect on biliary drainage, as 
determined by Poiseuille’s law,20 which holds that, 
for a fixed-pressure difference, flow is related to 
tube diameter to the fourth power. Maintenance 
of biliary drainage is critical in patients with ad-
vanced biliary cancer because it enables systemic 
chemotherapy to continue without major delay for 
stent change and avoids potentially life-threaten-
ing biliary sepsis. A small response in tumor bulk 
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Figure 3. Hazard Ratio, According to Trial and Prespecified Baseline Factors.
ABC denotes Advanced Biliary Cancer, and ECOG Eastern Cooperative Oncology Group. ECOG scores range from  
0 to 5, with lower scores indicating a higher level of functioning. The red line indicates the hazard ratio for death 
(0.64) in the intention-to-treat population.
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may therefore have a greater effect on survival 
than would be the case for other cancers.
Our data suggest that biliary tract cancers are 
sensitive to chemotherapy, a reality suggested but 
never proved by extant underpowered clinical data. 
Relatively little is known about the biology of bil-
iary tract cancer, but it appears to lie in the spec-
trum of gastrointestinal epithelial cancers with 
similar oncogenic mutations.21,22 Critical to the 
future rational treatment of biliary tract cancer 
is a molecular map with which targeted therapies 
may be directed, similar to that which is evolving 
for the common cancers.
In summary, this study shows a significant 
survival advantage for cisplatin plus gemcitabine 
over gemcitabine alone in patients with advanced 
biliary cancer. Cisplatin plus gemcitabine is an ap-
propriate option for the treatment of these pa-
tients.
Supported by the University College London Hospitals and 
University College London Comprehensive Biomedical Research 
Centre, University College London, Cancer Research United King-
dom, and an unrestricted educational grant from Lilly Oncology.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients and their families, without whom this 
trial would not have been possible; Allan Hackshaw, Helen 
Meadows, Jonathan Ledermann, and Faye Owen for their help 
with the trial design and an earlier version of the manuscript; 
and the independent data monitoring committee: Hugh Barr, 
M.D. (chair), Paul Lorigan, M.D., and Joan Morris, M.D.
Table 2. Grade 3 or 4 Toxic Effects during Treatment, According to Treatment Group.
Variable
Gemcitabine 
(N = 199)
Cisplatin plus Gemcitabine 
(N = 198) P Value
number (percent)
Hematologic toxic effects
Decreased white-cell count 19 (9.5) 31 (15.7) 0.07
Decreased platelet count 13 (6.5) 17 (8.6) 0.44
Decreased hemoglobin level 6 (3.0) 15 (7.6) 0.04
Decreased neutrophil count 33 (16.6) 50 (25.3) 0.03
Any hematologic toxic effect 47 (23.6) 64 (32.3) 0.05
Liver function
Increased alanine aminotransferase level 34 (17.1) 19 (9.6) 0.03
Other abnormal liver function 39 (19.6) 26 (13.1) 0.08
Any abnormal liver function 54 (27.1) 33 (16.7) 0.01
Nonhematologic toxic effects
Alopecia 0 2 (1.0) 0.16
Anorexia 5 (2.5) 6 (3.0) 0.75
Fatigue 33 (16.6) 37 (18.7) 0.58
Nausea 7 (3.5) 8 (4.0) 0.78
Vomiting 11 (5.5) 10 (5.1) 0.65
Impaired renal function 2 (1.0) 3 (1.5) 0.83
Infection
Without neutropenia 23 (11.6) 12 (6.1) 0.05
With neutropenia 14 (7.0) 20 (10.1) 0.28
Biliary sepsis 8 (4.0) 8 (4.0) 0.99
Any type 38 (19.1) 36 (18.2) 0.82
Deep-vein thrombosis 1 (0.5) 4 (2.0) 0.18
Thromboembolic event 3 (1.5) 7 (3.5) 0.20
Other 62 (31.2) 66 (33.3) 0.64
Any 100 (50.3) 108 (54.5) 0.39
Any grade 3 or 4 toxic effect 137 (68.8) 140 (70.7) 0.69
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Appendix
The recruiting sites and principal investigators in the ABC-02 study are as follows: Aberdeen Royal Infirmary — M. Nicholson; Addenbrooke’s 
Hospital — P. Corrie; Belfast City Hospital — M. Eatock; Bristol Royal Infirmary — S. Falk; Cheltenham General Hospital — S. Elyan; Christie 
Hospital — J. Valle (co-chief investigator); Cookridge Hospital — A. Anthony; Cumberland Infirmary — J. Nicoll; Derbyshire Royal Infirmary — R. 
Kulkarni; Dorset Cancer Centre — R. Osbourne; Glan Clwyd Hospital — A. Garcia Alonso; Hammersmith Hospital — H. Wasan (co-chief inves-
tigator); Maidstone Hospital — J. Waters; Mount Vernon Hospital — M. Harrison; Ninewells Hospital — D. Adamson; North Hampshire Hospital 
— C. Rees; North Middlesex Hospital — J. Bridgewater (co-chief investigator); Nottingham University Hospital — S. Madhusudan; Peterborough 
Hospital — K. McAdam; Princess Alexandra Hospital — J. Bridgewater (co-chief investigator); Princess Royal Hospital — A. Maraveyas; Queen 
Elizabeth Hospital Birmingham — D. Palmer; Royal Bournemouth Hospital — T. Hickish; Royal Free Hospital — T. Meyer; Royal Marsden Hospital 
— D. Cunningham; Royal South Hants Hospital — T. Iveson; Royal Surrey County Hospital — G. Middleton; St. Bartholomew’s Hospital — S. 
Slater; St. George’s Hospital — F. Lofts; St. Mary’s Hospital Portsmouth — C. Archer; Salisbury Hospital — T. Iveson; Southampton General Hospi-
tal — T. Iveson; University College Hospital — J. Bridgewater (co-chief investigator); Velindre Cancer Centre — S. Mukherjee; Weston Park Hos-
pital — J. Wadsley; Wrexham Maelor Hospital — S. Gollins.
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